Tapinarof Cream 1% QD for the Treatment of Plaque Psoriasis: Efficacy and Safety in Two Pivotal Phase 3 Trials

Main Article Content

Mark Lebwohl
Linda Stein Gold
Bruce Strober
April Armstrong
H Chih-Ho Hong
Leon Kircik
Jennifer Soung
Jeff Fromowitz
Scott Guenthner
Stephen Piscitelli
David Rubenstein
Philip Brown
Anna Tallman
Robert Bissonnette


Psoriasis, Aryl Hydrocarbon Receptor Modulating Agent, Tapinarof, Safety, Efficacy


Abstract not available.


1. Menter A, et al. J Am Acad Dermatol. 2008;58:826–850

2. Robbins K, et al. J Am Acad Dermatol. 2019;80:714–721

3. Stein Gold L, et al. J Am Acad Dermatol. 2020; doi: 10.1016/j.jaad.2020.04.181.

Most read articles by the same author(s)

<< < 3 4 5 6 7 8 9 10 11 12 > >>